Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
复制标题
DOI：
10.1126/science.278.5341.1295
复制
发表时间：
1997-11-14
期刊：
影响因子：
56.9
通讯作者：
Siliciano, RF
中科院分区：
文献类型：
--
作者：
Finzi, D;Hermankova, M;Siliciano, RF
研究了携带前病毒DNA的静止CD 4（+）T淋巴细胞为接受高效抗逆转录病毒治疗（HAART）的患者提供人类免疫缺陷病毒1型（HIV-1）储存库的假设。在一项对22名成功接受HAART治疗长达30个月的患者进行的研究中，常规地从静息的CD 4（+）T淋巴细胞中回收有复制能力的病毒。携带HIV-1的静息CD 4（+）T细胞的频率很低，每10（6）个细胞中有0.2至16.4个，并且在横断面分析中，并没有随着治疗时间的增加而减少。回收的病毒通常没有显示出与对相关抗逆转录病毒药物的耐药性相关的突变。在决定是否终止对HAART有反应的患者的治疗时，应考虑静止的CD 4（+）T细胞中的非进化潜伏病毒库。
The hypothesis that quiescent CD4(+) T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4(+) T lymphocytes. The frequency of resting CD4(+) T cells harboring talent HIV-l was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4(+) T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.